Trials / Unknown
UnknownNCT05002517
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab
Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Against Systemic Corticotherapy in Patients Admitted by Covid-19 With Bilateral Pneumonia and Poor Evolution
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Biogipuzkoa Health Research Institute · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
Randomized, open, single-center, controlled clinical trial, with 2 treatment arms that seeks to demonstrate the effectiveness of tocilizumab against systemic corticosteroids, both treatments added to supportive treatment in patients admitted for COVID-19 with bilateral pneumonia and poor evolution
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tociliziumab group | Tocilizumab is a humanized recombinant IgG1 monoclonal antibody to human interleukin-6 (IL-6) receptor, produced in Chinese hamster ovary cells by recombinant DNA technology. |
| DRUG | Methylprednisolone group | Methylprednisolone belongs to a group of medicines called corticosteroids (it works at the cellular level by reducing the production of substances that cause inflammation or allergy). |
Timeline
- Start date
- 2020-09-03
- Primary completion
- 2021-07-31
- Completion
- 2021-10-31
- First posted
- 2021-08-12
- Last updated
- 2021-08-12
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05002517. Inclusion in this directory is not an endorsement.